ChromaDex (NASDAQ:CDXC) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of ChromaDex (NASDAQ:CDXC) from a buy rating to a strong-buy rating in a research note issued to investors on Monday.

Other equities research analysts have also issued research reports about the stock. HC Wainwright increased their price objective on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Monday, November 4th. Roth Mkm increased their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th.

ChromaDex Price Performance

CDXC opened at $5.50 on Monday. ChromaDex has a fifty-two week low of $1.51 and a fifty-two week high of $7.97. The firm has a market capitalization of $420.11 million, a PE ratio of 550.55 and a beta of 2.21. The company’s 50-day moving average is $5.62 and its 200 day moving average is $5.00.

Insider Activity

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the firm’s stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $6.19, for a total value of $230,026.59. Following the completion of the transaction, the director now directly owns 244,179 shares of the company’s stock, valued at approximately $1,511,468.01. This trade represents a 13.21 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 9.64% of the company’s stock.

Institutional Trading of ChromaDex

Several institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC lifted its stake in ChromaDex by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,154,778 shares of the company’s stock worth $6,128,000 after purchasing an additional 5,186 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its stake in ChromaDex by 1,785.9% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,011,290 shares of the company’s stock worth $5,365,000 after purchasing an additional 957,665 shares in the last quarter. Renaissance Technologies LLC lifted its stake in ChromaDex by 68.0% in the 4th quarter. Renaissance Technologies LLC now owns 712,788 shares of the company’s stock worth $3,781,000 after purchasing an additional 288,588 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in ChromaDex by 288.1% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 662,956 shares of the company’s stock worth $3,517,000 after purchasing an additional 492,148 shares in the last quarter. Finally, State Street Corp lifted its stake in ChromaDex by 11.3% in the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock worth $2,256,000 after purchasing an additional 62,692 shares in the last quarter. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.